Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core
- 333 Downloads
Current medications for attention-deficit/hyperactivity disorder (ADHD) include some single isomer compounds [dextroamphetamine (d-amphetamine, dexedrine) and dexmethylphenidate (Focalin)] and some racemic compounds [methylphenidate and mixed-salts amphetamine (Adderall)]. Adderall, which contains approximately 25% l-amphetamine, has been successfully marketed as a first-line medication for ADHD. Although different clinical effects have been observed for d-amphetamine, Adderall, and benzedrine; potential psychopharmacological differences on the level of neurotransmission between d-amphetamine and l-amphetamine have not been well characterized.
To evaluate potential differences in the isomers, we used the technique of high-speed chronoamperometry with Nafion-coated single carbon-fiber microelectrodes to measure amphetamine-induced release of dopamine (DA) in the striatum and nucleus accumbens core of anesthetized male Fischer 344 rats. Amphetamine solutions were locally applied by pressure ejection using micropipettes.
The presence of l-amphetamine in the d,l-amphetamine solutions did not cause increased release of DA but did change DA release kinetics. The d,l-amphetamine-evoked signals exhibited significantly faster rise times and shorter signal decay times. This difference was also observed in the nucleus accumbens core. When l-amphetamine was locally applied, DA release was not significantly different in amplitude, and it exhibited the same rapid kinetics of d,l-amphetamine.
These data support the hypothesis that amphetamine isomers have different effects on release of DA from nerve endings. It is possible that l-amphetamine may have unique actions on the DA transporter, which is required for the effects of amphetamine on DA release from nerve terminals.
KeywordsAmphetamines Psychostimulants Dopamine Voltammetry Striatum Nucleus accumbens
These studies were supported by USPHS grants MH066393, MH01245, DA14944, and NS39787. l-Amphetamine was donated by NIH–NIDA/Division of Neuroscience & Behavioral Research. These experiments comply with all laws within the United States of America.
- Goodman M, Nachman G (2000) The ADHD market: it’s time to pay attention. Morgan Stanley Dean Witter, New YorkGoogle Scholar
- Goodman LS, Gilman A, Hardman JG, Limbird LE, Gilman AG (2001) Goodman & Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New YorkGoogle Scholar
- Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, SydneyGoogle Scholar
- Smith RC, Davis JM (1977) Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man. Psychopharmacology (Berl) 53:1–12Google Scholar
- Solanto MV, Arnsten AFT, Castellanos FX (2001) Stimulant drugs and ADHD: basic and clinical neuroscience. Oxford University Press, New YorkGoogle Scholar